An update on the genetic causes and treatment of hypophosphatemic rickets
Article information
Abstract
Hypophosphatemic rickets (HR) results from impaired renal phosphate reabsorption caused either by genetic defects in renal phosphate cotransporters or by increased levels of phosphaturic mediators (phosphatonins). Fibroblast growth factor 23 (FGF23) is the principal regulator of phosphate metabolism and interacts with several hormonal and molecular pathways to maintain phosphate homeostasis. Variants in genes such as PHEX, FGF23, DMP1, ENPP1, FAM20C, and others lead to inherited forms of HR, and HR may also occur as part of several syndromic conditions. Affected patients typically present with short stature, skeletal deformities, bone pain, muscle weakness, dental abnormalities, and characteristic radiographic abnormalities. Laboratory findings usually include hypophosphatemia, normal or mildly elevated parathyroid hormone levels, and markedly increased alkaline phosphatase. Conventional therapy with oral phosphate and active vitamin D improves many metabolic abnormalities but rarely leads to full correction. The development of burosumab, a monoclonal antibody targeting FGF23, has transformed treatment by improving biochemical parameters, rickets severity, growth, and quality of life. This review summarizes current knowledge regarding the molecular mechanisms, clinical manifestations, diagnostic work-up, classification, and treatment strategies for HR, with particular emphasis on advances in targeted therapy.
Highlights
· Fibroblast growth factor 23 (FGF23) plays a central role in the pathophysiology of hypophosphatemic rickets.
· Genetic and molecular advances have improved the diagnosis and classification of hypophosphatemic rickets.
· Burosumab has transformed the treatment of FGF23-mediated hypophosphatemic rickets.
Introduction
Rickets results from impaired mineralization of the bone matrix and epiphyseal growth plates in children and adolescents [1]. The condition primarily results from disturbances in calcium, phosphate, and vitamin D balance, which are essential for normal skeletal development. Rickets presents with delayed closure of the fontanelles, frontal bossing, craniotabes, dental abnormalities, enlargement of the wrists and ankles, and genu varum/valgum deformities that become apparent after the onset of walking [1,2]. Although nutritional vitamin D deficiency remains the leading cause worldwide, hereditary and acquired disorders affecting phosphate metabolism may also cause hypophosphatemic rickets (HR) [3]. HR results from impaired renal phosphate reabsorption or increased levels of phosphaturic factors. This review presents the pathophysiology, classification, and treatment approaches for HR.
Phosphate metabolism and FGF23
Phosphorus, the most abundant intracellular anion in the human body, exists primarily as inorganic phosphate. It participates in various biological processes, including acid–base balance, cell membrane function, energy metabolism, intracellular signaling, protein phosphorylation, and nucleotide and phospholipid metabolism [4]. Approximately 90% of total body phosphate is stored in the skeleton as calcium phosphate (hydroxyapatite) crystals, about 9% is found in soft tissues, and only 1% circulates in the extracellular compartment [5,6].
Dietary phosphate is absorbed in the duodenum and jejunum by passive paracellular diffusion or active transcellular transport. When intake is low, absorption shifts toward the active transcellular pathway mediated by sodium–phosphate cotransporter 2b (NaPi-2b) in enterocytes [7]. After absorption, phosphate is used by cells in various biological processes, stored in bone tissue, or excreted by the kidneys. Approximately 90% of plasma phosphate is filtered by the glomeruli, and 80%–85% of the filtered phosphate is reabsorbed in the proximal tubules through the sodium-phosphate cotransporters NaPi-2a and NaPi-2c [8]. Thus, serum phosphate levels are maintained within a narrow range through the coordinated actions of the intestine, kidneys, and various hormones.
Vitamin D and parathyroid hormone (PTH) are key regulators of phosphate balance. PTH acts through PTH receptor 1 (PTHR1), a G-protein-coupled receptor, to decrease NaPi-2a and NaPi-2c expression, thereby reducing proximal tubular phosphate reabsorption [4]. PTH also stimulates 1α-hydroxylase, increasing 1,25-dihydroxyvitamin D (1,25(OH)2D) levels and thereby enhancing intestinal phosphate absorption to help restore serum phosphate [2,4]. In addition to vitamin D and PTH, several phosphaturic proteins (phosphatonins)—including fibroblast growth factor 23 (FGF23), matrix extracellular phosphoglycoprotein, secreted frizzled-related protein 4, and FGF7—contribute to phosphate homeostasis [9, 10]. Among these, FGF23 is the principal hormone regulating renal phosphate excretion and plays a central role in disorders characterized by hypophosphatemia [11].
FGF23 is primarily expressed by osteocytes and osteoblasts. It is synthesized as a 251-amino-acid prohormone consisting of three major domains: the signal sequence, the central FGF homology domain, and the C-terminal domain. Following intracellular cleavage of the signal sequence, intact FGF23 (iFGF23) is O-glycosylated at threonine 178 by polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3). This O-glycosylation prevents proteolysis of iFGF23 and facilitates secretion of the resulting 32-kDa, 227-amino-acid glycoprotein [12]. Alternatively, iFGF23 can be cleaved intracellularly by subtilisin-like proprotein convertases at the protease recognition site (R176XXR179), generating biologically inactive N- and C-terminal FGF23 fragments [9,12]. Furthermore, it has been shown that family with sequence similarity 20, member C (FAM20C) phosphorylates Ser180 in iFGF23 and thereby inhibits O-glycosylation by GALNT3, which accelerates FGF23 cleavage and inactivation by subtilisin-like proprotein convertases [13]. Thus, GALNT3-mediated O-linked glycosylation and proteolytic inactivation of iFGF23 are tightly regulated to maintain phosphate homeostasis.
FGF23 levels are influenced by several factors, including high dietary or serum phosphate levels, calcium, PTH, 1,25(OH)2D, and metabolic acidosis. Serum phosphate and FGF23 levels are closely related. In healthy individuals, FGF23 levels increase in response to elevated serum phosphate and decrease when serum phosphate levels fall [10]. In addition, FGF23 decreases 1,25(OH)2D by inhibiting 1α-hydroxylase and increases the formation of 24,25(OH)2D3, an inactive vitamin D metabolite, by activating 24-hydroxylase [2,10].
FGF23 exerts its phosphaturic effect by activating FGF receptor 1 (FGFR1) [11,12]. The transmembrane protein α-klotho acts as an obligate coreceptor for this effect. α-klotho is predominantly expressed in proximal convoluted tubules and the chief cells of the parathyroid glands. Experimental studies have shown that serum FGF23 levels increase in α-klotho knockout mice, yet serum phosphate levels remain high, highlighting the importance of α-klotho for the phosphaturic activity of FGF23 [14,15].
Another important regulator is sodium-hydrogen exchanger regulatory factor 1 (NHERF1) [11]. It modulates phosphate handling through 2 actions: attenuating PTH-induced cyclic AMP generation via interaction with PTHR1 and stabilizing NaPi-2a at the apical membrane [16]. Loss-of-function mutations in NHERF1 lead to phosphate wasting, hypophosphatemia, and hypercalcemia [17]. Fig. 1 schematically summarizes phosphate homeostasis.
Schematic representation of phosphate homeostasis. DMP1, dentin matrix acidic phosphoprotein 1; FAM20C, family with sequence similarity 20 member C; ENPP1, ectonucleotide pyrophosphatase/phosphodiesterase 1; PHEX, phosphate-regulating endopeptidase homolog, X-linked; FGF23, fibroblast growth factor 23; GALNT3, polypeptide N-acetylgalactosaminyltransfera se 3; FGFR1c, fibroblast growth factor receptor 1c; Na/Pi, sodiumphosphate cotransporter; 1,25(OH)2D, 1,25-dihydroxyvitamin D.
Clinical features of HR
HR comprises a group of disorders characterized by impaired bone mineralization due to disruption of phosphate homeostasis. It is estimated to occur in 1 in 20,000 live births [17]. Diagnosis is based on a combination of clinical, biochemical, and radiographic findings. The main clinical manifestations include short stature, bone pain, muscle weakness, dental abscesses, delayed tooth eruption, enlargement of the wrists, ankles, and costochondral joints, frontal bossing, and genu varum or valgum deformities that become apparent after the onset of walking. Because maternal phosphate transfer protects the fetus in utero, signs of rickets are generally absent in the neonatal period; however, deformities develop progressively as mechanical loading increases on inadequately mineralized bone after walking begins. Chiari type 1 malformation has been reported in up to 25% of children with X-linked HR (XLHR) and may be asymptomatic or present with headache, vomiting, papilledema, or neurologic symptoms [18]. Radiographic features include irregular metaphyseal margins, metaphyseal cupping and fraying, poor mineralization of the epiphyseal center, and widening of the growth plates [2,5]. In adults, calcification of the tendons, ligaments, and joint capsules, known as enthesopathy, may occur and contribute to joint pain and reduced mobility [19]. Fig. 2 shows the clinical and radiographic features of a patient with HR.
Clinical and radiographic features of a patient with hypophosphatemic rickets. (A) Genu varum deformity. (B) Enlargement of the costochondral joints. (C) Enlargement of the wrists. (D) Irregularity of the metaphyseal border, metaphyseal cupping, and fraying. Figure created from the authors’ own archive. Written informed consent for publication of these images was obtained from the patient’s parents.
Normal serum phosphate levels vary with age and must therefore be interpreted using age-appropriate reference ranges. Normal serum phosphate levels are 4.8–8.2 mg/dL at 0–5 days, 3.8–6.5 mg/dL at 1–3 years, 3.7–5.6 mg/dL at 4–11 years, 2.9–5.4 mg/dL at 12–15 years, and 2.7–4.7 mg/dL at 16–19 years [2,20]. Tubular reabsorption of phosphate (TRP) is commonly used to assess renal phosphate handling and is calculated as 1 − (urine phosphate × serum creatinine)/(serum phosphate × urine creatinine). TRP values of 75%–85% are classically considered within the lower normal range only when serum phosphate is normal. When hypophosphatemia is present, the kidney should reabsorb nearly all filtered phosphate; therefore, TRP should be ≥95%. Another useful indicator is the tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR), which is often superior for identifying renal phosphate wasting. It can be determined using the Walton-Bijvoet nomogram or calculated as follows: (1) for TRP ≤86%, TmP/GFR = TRP × serum phosphate; and (2) for TRP >86%, TmP/GFR = (0.3 × TRP)/[1 − (0.8 × TRP)] × serum phosphate [21]. Age-dependent reference values must also be considered; a low TmP/GFR in the presence of hypophosphatemia strongly suggests renal phosphate wasting [22]. Age-specific normal TmP/GFR ranges are 3.6–8.6 at birth, 3.7–8.2 at 3 months, 2.9–6.5 at 6 months, 2.9–6.1 at 2–15 years, and 2.2–3.6 mg/dL in adults.
Hypophosphatemia, normal or slightly elevated serum PTH levels, and markedly elevated serum alkaline phosphatase (ALP) levels are typical laboratory findings in HR. In comparative studies, children with vitamin D–dependent rickets had the highest PTH and ALP concentrations, whereas those with HR had lower values, emphasizing the importance of differential interpretation [23]. Normal calcium, low phosphate, and high ALP levels may also occur in stage 2 calciopenic rickets due to vitamin D deficiency or synthesis defects. This possibility should be considered in the differential diagnosis. Serum PTH can help distinguish these entities: PTH is markedly elevated in calciopenic rickets but is usually normal or only mildly elevated in HR [2,24]. However, serum PTH levels may be very high in the extremely rare patient with HR and hyperparathyroidism, potentially mimicking calciopenic rickets [2]. Serum FGF23 is another useful laboratory marker for differentiating forms of HR. Normal or elevated FGF23 with low or inappropriately normal 1,25(OH)2D suggests FGF23-dependent HR. In contrast, high 1,25(OH)2D with suppressed FGF23 suggests an FGF23-independent form. FGF23 activity is a key marker for the classification and treatment selection of HR. HR disorders can therefore be broadly classified as FGF23-dependent or as FGF23-independent disorders affecting transporters that are essential for renal phosphate reabsorption. To date, several genetic and acquired types of HR have been described (Table 1). The laboratory characteristics of the various types are summarized in Table 2.
FGF23-dependent HR
This group of disorders is characterized by hypophosphatemia, renal phosphate wasting, normal serum calcium, elevated ALP, inappropriately normal or low 1,25(OH)2D, normal or mildly increased PTH, and normal or elevated FGF23 concentrations.
1. X-linked HR
XLHR (MIM 307800) is the most common type of HR, with an estimated frequency of 1 in 20,000 live births. It results from inactivating mutations in PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome), which is located at Xp22.1, contains 22 exons, and encodes a 749-amino-acid protein [2,25]. Although inheritance is X-linked dominant, clinical severity may vary widely among affected females because of random X-inactivation [16]. PHEX is mainly expressed in mature osteoblasts and odontoblasts and is thought to regulate FGF23 through its endopeptidase activity. Inactivating mutations in PHEX lead to elevated serum FGF23 levels through a mechanism that remains incompletely understood. Several mechanisms have been proposed. PHEX is thought to prevent the accumulation of mineralization-inhibiting peptides, such as ASARM (acidic serine- and aspartic acid-rich motif) peptides, which otherwise stimulate FGF23 expression in osteocytes [26,27]. In addition, PHEX may also contribute to the proteolytic cleavage of FGF23 through its endopeptidase activity. Together, these mechanisms may contribute to the elevated FGF23 levels observed in PHEX-related HR [28].
More than 1,000 variants have been reported in the HGMD database to date (accessed Nov 6, 2025): 214 missense/nonsense variants, 193 small/gross deletions, 103 splice-site variants, 88 small/gross insertions, 13 small indels, 4 regulatory variants, and 5 complex rearrangements (https://www.hgmd.cf.ac.uk/ac/all.php). Variants in PHEX are distributed throughout the gene, and no clear genotype-phenotype relationship has been demonstrated. In addition, some variants have been identified in the 5' UTR, a noncoding region; therefore, sequencing this region of PHEX is important when determining the genetic etiology [29]. In studies conducted in Turkey, PHEX variants are the most frequently reported genetic defect among patients with HR, accounting for 80%–90% of cases [30-32].
Clinically, children typically present in late infancy or early childhood with wrist and ankle enlargement, rachitic rosary, lower-limb deformities, frontal bossing, dental abscesses, and bone pain. Osteomalacia, bone pain, and spinal canal stenosis are prominent in adults. The clinical phenotype is highly variable, and disease severity may differ even among affected members of the same family.
Genetic confirmation is most reliably achieved by sequencing the 22 coding exons and exon-intron junctions of PHEX. Sanger sequencing or next-generation sequencing identifies approximately 85% of mutations [33,34]. The remaining cases often involve copy-number alterations detectable by multiplex ligation-dependent probe amplification [34].
2. Autosomal dominant HR
Autosomal dominant HR (ADHR, MIM 193100) is caused by gain-of-function variants in the FGF23 gene. These variants typically occur at the subtilisin-like proprotein convertase cleavage site (R176XXR179) and render the molecule resistant to proteolytic inactivation. As a consequence, intact (biologically active) FGF23 accumulates, leading to renal phosphate wasting and reduced synthesis of 1,25(OH)2D [2,4,35].
Furin is a proteolytic enzyme that plays a crucial role in regulating circulating intact FGF23 levels. By facilitating FGF23 degradation, furin contributes to the maintenance of phosphate homeostasis [26]. In ADHR, despite normal PHEX and furin activity, mutant FGF23 is resistant to proteolytic processing. Consequently, circulating mutant FGF23 accumulates, increasing renal phosphate excretion and producing the typical HR phenotype.
ADHR is rarer than XLHR. To date, 35 different variants (34 missense/nonsense and 1 gross deletion) are listed in HGMD (accessed Nov 6, 2025). The clinical, laboratory, and radiographic features of ADHR are similar to those of XLHR. Unlike XLHR, ADHR is inherited in an autosomal dominant manner, and clinical findings may vary because of incomplete penetrance [36]. Some affected children experience spontaneous normalization of renal phosphate handling and improvement of symptoms over time [37]. Differences in age at onset, disease severity, and remission patterns appear to correlate with circulating FGF23 concentrations [38]. Several studies have also demonstrated relationships between markers of iron metabolism and both intact and C-terminal FGF23 levels. Iron deficiency may increase FGF23 production and the levels of its cleavage fragments, thereby precipitating hypophosphatemia. Consequently, assessment and correction of iron deficiency should be considered an important component of ADHR management [39,40].
3. Autosomal recessive HR
1) Autosomal recessive HR type 1 (ARHR1)
Autosomal recessive HR (ARHR) type 1 (ARHR1, MIM 241520) results from biallelic inactivating variants in the dentin matrix acidic phosphoprotein 1 (DMP1) gene (MIM 600980) [41]. DMP1 encodes a member of the SIBLING (small integrin-binding ligand N-linked glycoprotein) family that is highly expressed in osteoblasts and osteocytes and plays a critical role in bone mineralization [2,42]. DMP1 inhibits FGF23 expression [2,16]. Inactivating variants in DMP1 lead to inappropriate elevation of FGF23, renal phosphate wasting, and consequently an HR phenotype. The clinical, laboratory, and radiographic findings are similar to those of XLHR and ADHR [2]. In DMP1-knockout mouse models, markedly increased FGF23 levels are accompanied by severe bone, cartilage, and dental abnormalities, profound hypophosphatemia, and osteomalacia [43,44]. A characteristic feature that may distinguish ARHR1 from other forms is osteosclerosis of the skull base and calvaria [16]. Individuals carrying monoallelic variants may show increased renal phosphate excretion, mild hypophosphatemia, or focal osteomalacia on bone biopsy, yet typical clinical manifestations of rickets may be absent [45]. A total of 27 DMP1 variants associated with ARHR1 have been reported in HGMD (accessed Nov 6, 2025).
2) ARHR type 2
ARHR type 2 (ARHR2, MIM 613312) is caused by biallelic inactivating variants in the ENPP1 gene, which encodes ectonucleotide pyrophosphatase/phosphodiesterase-1. ENPP1 is expressed in chondrocytes, bone, and plasma cells. The ENPP1 gene is located at 6q22–q23 and consists of 25 exons. ENPP1 catalyzes the generation of extracellular pyrophosphate, an important inhibitor of hydroxyapatite crystal formation, and therefore plays a central role in controlling tissue mineralization [2,46,47]. Experimental studies have shown that inactivating variants in ENPP1 cause severe defects in the architecture of long bones [48].
Inactivating ENPP1 variants reduce extracellular pyrophosphate, promoting ectopic calcification while simultaneously increasing FGF23 production and renal phosphate wasting. Consequently, patients may present with typical manifestations of HR together with vascular and soft-tissue calcifications, particularly involving the coronary arteries and other large arteries [48-50]. Generalized arterial calcification of infancy (GACI; MIM 208000) is inherited in an autosomal recessive manner and, in severe cases, may be life-threatening during the neonatal period [50]. To date, 189 different ENPP1 variants have been listed in HGMD; most are missense or nonsense variants (accessed Nov 6, 2025).
3) ARHR type 3
ARHR type 3 (ARHR3), also known as Raine syndrome (MIM 259775), was first described by Raine et al. [51] in 1989 in a patient with generalized osteosclerosis and severe craniofacial dysmorphism. It is inherited in an autosomal recessive manner and is classically regarded as lethal in the neonatal period; however, an increasing number of nonlethal cases have recently been reported [52].
ARHR3 results from loss-of-function variants in FAM20C, also referred to as DMP4 (dentin matrix protein 4) [53]. FAM20C is predominantly expressed in osteoblasts, odontoblasts, and ameloblasts in skeletal and dental tissues [54]. Patients with milder, nonlethal forms may exhibit elevated FGF23 levels, hypophosphatemia that tends to improve with age, ectopic calcifications (including intracranial calcifications), osteosclerosis, and severe early-onset dental decay [55]. Experimental studies have shown that FAM20C-null mice develop hypophosphatemia, elevated intact FGF23, inappropriately normal 1,25(OH)2D concentrations, rickets, and pronounced dental abnormalities [56]. These studies also indicate that FAM20C suppresses FGF23 by increasing DMP1 expression; loss-of-function mutations in FAM20C reduce DMP1 expression, resulting in FGF23-dependent hypophosphatemia [56,57]. In addition, FAM20C promotes FGF23 degradation by phosphorylating Ser180 of FGF23 and inhibiting GALNT3-mediated O-glycosylation of Thr178. Accordingly, loss-of-function mutations in FAM20C reduce FGF23 cleavage and increase serum FGF23 levels, resulting in hypophosphatemia [13].
4. Other causes of FGF23-dependent HR
1) Osteoglophonic dysplasia
Osteoglophonic dysplasia (OGD, MIM 166250) results from heterozygous activating variants in FGFR1 and is inherited in an autosomal dominant manner. OGD is a rare skeletal dysplasia characterized by craniosynostosis, rhizomelic short stature, maxillary hypoplasia, depressed nasal bridge, mandibular prognathism, dental anomalies, a tower-shaped skull, vertebral abnormalities, and defective bone mineralization with metaphyseal changes. Metaphyseal radiolucencies may also be evident on skeletal radiographs [2,58]. Several affected individuals have been reported to have elevated circulating FGF23, renal phosphate wasting, hypophosphatemia, and reduced 1,25(OH)2D concentrations [59]. These findings suggest that activating FGFR1 variants may stimulate FGF23 secretion from bone, thereby contributing to phosphate wasting and rickets-like manifestations [4].
2) McCune-Albright syndrome
McCune-Albright syndrome is a heterogeneous disorder characterized by polyostotic fibrous dysplasia, caféau-lait (hyperpigmented) skin macules, and peripheral precocious puberty; it may also be accompanied by additional endocrine abnormalities resulting from autonomous hormone production, such as hyperthyroidism, hypercortisolism, and growth hormone excess. Fibrous dysplasia most commonly involves the femur, craniofacial skeleton, and pelvic bones, typically appears before 10 years of age and frequently affects the craniofacial region [60]. The disorder results from somatic postzygotic activating variants in GNAS. Approximately half of affected individuals develop elevated FGF23 levels, renal phosphate wasting, and hypophosphatemia. Despite these biochemical abnormalities, the classical skeletal manifestations of HR are rarely observed in McCune-Albright syndrome [60-62].
3) Opsismodysplasia
Opsismodysplasia (OPSMD, MIM 258480) derives its name from the Greek word “opsismo,” meaning delayed maturation. This extremely rare skeletal dysplasia is inherited in an autosomal recessive manner and results from biallelic variants in the INPPL1 gene [63]. Clinically, OPSMD is characterized by markedly short limbs, small hands and feet, a wide anterior fontanelle, anteverted nose, depressed nasal bridge, prominent brow, long philtrum, and generalized hypotonia. Radiographic findings typically include severe platyspondyly, square-shaped metacarpals, delayed epiphyseal ossification, and metaphyseal cupping [64,65]. In 2 reported cases, OPSMD was accompanied by renal phosphate wasting and features consistent with HR; in one of these patients, serum FGF23 concentrations were elevated, suggesting a possible mechanistic link between INPPL1 dysfunction and phosphate metabolism [65].
4) HR with hyperparathyroidism
HR with hyperparathyroidism (MIM 612089) is characterized by hypophosphatemia and diffuse parathyroid hyperplasia [2]. The condition is thought to arise from a balanced chromosomal translocation involving breakpoints at 9q21.13 and 13q13.1, located near the gene encoding α-klotho, the obligate coreceptor for FGFR1, the principal receptor mediating FGF23 signaling. This rearrangement results in overexpression of α-klotho, thereby enhancing FGFR1 bioactivity [66]. Excess α-klotho not only amplifies the phosphaturic actions of FGF23 but also promotes parathyroid hyperplasia and autonomous PTH secretion independently of FGF23. Consequently, hypophosphatemia becomes more pronounced, and serum phosphate levels tend to be lower than those typically observed in XLHR [66]. To date, the disorder has been described in only 1 patient. Biochemical findings included marked renal phosphate wasting, hypophosphatemia, elevated PTH, normal or low 1,25(OH)2D, and increased circulating FGF23 concentrations with enhanced bioactivity. The increase in FGF23 is believed to reflect upregulated signaling through the FGFR1–α-klotho pathway rather than primary overproduction of the hormone itself [66].
5) Epidermal nevus syndrome
Epidermal nevus syndrome (ENS) represents a rare and heterogeneous group of disorders characterized by epidermal nevi in association with extracutaneous abnormalities, most commonly involving the central nervous system, eyes, and skeleton. Genetic studies have linked ENS to postzygotic activating variants in RAS genes (HRAS, KRAS) [67].
Several reports have demonstrated that affected individuals may develop hypophosphatemia due to elevated circulating FGF23 levels [68]. Initially, the epidermal nevus itself was believed to be the source of excess FGF23, and surgical excision or ablative procedures were therefore proposed in some cases. However, with improved understanding of the disease pathophysiology, this approach has largely been abandoned because it rarely corrects the underlying phosphate imbalance [69].
6) Serum/glucocorticoid-regulated kinase 3-associated HR
This disorder, also described as autosomal dominant HR, was first reported in 2020 by Cebeci et al. [70] in five affected females from three generations of the same family. After known genetic causes of HR were excluded, a potentially pathogenic SGK3 variant (c.979-96T> A, NM_013257.4) was identified in all patients [70]. Serum/glucocorticoid-regulated kinase 3 (SGK3) is thought to participate in renal phosphate reabsorption by upregulating the NaPi-2a cotransporter, thereby enhancing proximal tubular phosphate uptake [71]. In these patients, serum FGF23 concentrations were normal, whereas 1,25(OH)2D levels were inappropriately low or normal despite persistent hypophosphatemia. Experimental studies in SGK3-knockout mice have demonstrated renal phosphate wasting and impaired bone mineralization, supporting a role for SGK3 in phosphate homeostasis [72]. Because data are limited and the pathogenic mechanism remains unclear, additional studies are required to determine the precise classification of this condition within the spectrum of HR.
7) Tumor-induced osteomalacia
Tumor-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a rare paraneoplastic disorder characterized by the secretion of phosphatonins, most notably FGF23. Excess phosphatonin activity causes renal phosphate wasting, hypophosphatemia, and inappropriately normal or low 1,25(OH)2D levels, which can result in HR/osteomalacia [73]. Clinical features include bone pain, muscle weakness, and recurrent fractures. The causative lesions are benign mesenchymal tumors that may arise anywhere in the body, either in bone or soft tissue [73]. Because they are often small and slow-growing, they may be difficult to localize and sometimes remain undetected for years [47]. Therefore, TIO should be suspected in patients with hypophosphatemia and increased renal phosphate wasting in the presence of elevated FGF23. However, it should be remembered that other phosphatonins may contribute to the disease in patients in whom elevated FGF23 cannot be demonstrated [73]. The primary treatment is complete surgical excision of the tumor with appropriate margins, guided by imaging. In certain instances, complete resection is not feasible because of tumor inaccessibility or the risk of substantial postoperative morbidity. In such cases, radiofrequency ablation or cryoablation may be considered. In cases where the tumor cannot be identified or completely removed, medical therapy involving oral phosphate and active vitamin D is indicated [47,73]. Furthermore, burosumab, a monoclonal antibody that targets FGF23, has been suggested as a promising treatment for TIO [47,73].
8) Neurofibromatosis type 1
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterized by café-au-lait spots and cutaneous plexiform neurofibromas. The condition results from mutations in the NF1 tumor suppressor gene on chromosome 17. Cases of elevated serum FGF23 levels and hypophosphatemic osteomalacia have been reported [74]. The underlying mechanism responsible for the increase in serum FGF23 remains unclear. Despite the initial attribution of increased FGF23 to neurofibromas, the clinical responses following tumor excision have been inconsistent [75].
FGF23-independent HR
The common features of this group of hypophosphatemic disorders include elevated serum 1,25(OH)2D levels secondary to hypophosphatemia, together with increased renal phosphate excretion. Importantly, this mechanism is independent of FGF23. The rise in active vitamin D enhances intestinal calcium absorption and suppresses PTH. As a consequence, hypercalciuria of varying severity and nephrocalcinosis/nephrolithiasis may occur.
1. Hereditary HR with hypercalciuria
Hereditary HR with hypercalciuria (HHRH, MIM 241530) is caused by inactivating variants in SLC34A3 (solute carrier family 34 [type II sodium/phosphate cotransporter], member 3), which encodes the NaPi-2c transporter [76]. Loss of NaPi-2c function results in increased renal phosphate wasting and consequent hypophosphatemia [2,4]. Secondary to hypophosphatemia, serum 1,25(OH)2D levels rise, intestinal calcium absorption increases, PTH is suppressed, and hypercalciuria and/or nephrocalcinosis may develop [2]. In patients with homozygous or compound heterozygous SLC34A3 variants, HHRH presents with variable severity, including metabolic bone disease and nephrolithiasis/nephrocalcinosis [59,76]. Interestingly, heterozygous carriers are not uniformly asymptomatic and may manifest mild hypophosphatemia, idiopathic hypercalciuria, and/or elevated 1,25(OH)2D levels later in life [77]. To date, 130 different variants (27 missense/nonsense, 12 splice sites, 12 small deletions, 5 gross deletions, 1 small insertion, and 1 small indel) have been listed in HGMD (accessed Nov 6, 2025). The clinical manifestations of the disease vary substantially, and a definitive genotype–phenotype correlation remains to be elucidated.
2. HR with nephrolithiasis and osteoporosis type 1
SLC34A1, also known as solute carrier family 34 member 1, encodes the NaPi-2a cotransporter, which plays a critical role in phosphate reabsorption in the proximal tubule. Inactivating homozygous variants in this gene have been associated with several overlapping clinical syndromes, including HR with nephrolithiasis and osteoporosis type 1 (NPHLOP1; MIM 612286), Fanconi renotubular syndrome 2 (FRTS2; MIM 613388), and infantile hypercalcemia type 2 (HCINF2; MIM 616963) [78,79]. The main feature of these disorders is increased renal phosphate wasting due to impaired NaPi-2a function. The clinical phenotypes of these disorders range from mild to severe. Monoallelic SLC34A1 mutations cause NPHLOP1, whereas biallelic inactivating mutations result in FRTS2 or HCINF2. NPHLOP1 is classically inherited in an autosomal dominant manner and was initially described in adults with heterozygous SLC34A1 mutations who presented with increased renal phosphate wasting, hypercalciuria, nephrolithiasis, and osteoporosis [78]. Similar to HHRH, NPHLOP1 is characterized by increased phosphate excretion due to impaired proximal tubular reabsorption, hypophosphatemia, elevated 1,25(OH)2D synthesis, hypercalciuria, appropriately suppressed FGF23, nephrocalcinosis, and osteopenia [78-80]. In some patients, the clinical presentation may be mild and limited to recurrent kidney stones [81].
FRTS2 is an autosomal recessive form of renal Fanconi syndrome and is extremely rare. It is characterized by increased renal phosphate wasting, hypercalciuria, aminoaciduria, glucosuria, elevated 1,25(OH)2D levels, normal PTH, impaired growth, skeletal deformities in childhood (rickets), osteomalacia in adulthood, and recurrent fractures. Metabolic analyses reveal a proximal tubulopathy without a renal acidification defect [80,82]. The pathogenesis of the proximal tubulopathy remains unclear, and further studies are needed to elucidate the mechanisms leading to this defect.
HCINF2 is characterized by vomiting, feeding difficulties, polyuria, severe dehydration, hypotonia, and growth retardation. Laboratory findings include increased renal phosphate wasting, hypophosphatemia, elevated 1,25(OH)2D, low serum FGF23, hypercalcemia, suppressed PTH, hypercalciuria, nephrocalcinosis, and low-molecular-weight proteinuria [83,84].
3. Nephrolithiasis/osteoporosis, hypophosphatemic, 2
Nephrolithiasis/osteoporosis, hypophosphatemic, 2 (NPHLOP2; MIM 612287) is an autosomal dominant disorder caused by monoallelic variants in SLC9A3R1 (solute carrier family 9, sodium/hydrogen exchanger regulatory factor 1; MIM 604990), which encodes NHERF1 [11]. NHERF1 functions as an adaptor protein that promotes renal phosphate reabsorption. It regulates NaPi-2a expression and inhibits PTH-mediated activation of protein kinase A through its interaction with PTHR1 [11]. Heterozygous inactivating variants in SLC9A3R1 result in reduced NaPi-2a expression and impaired modulation of PTH signaling. Similar to HHRH and NPHLOP1, NPHLOP2 is characterized by increased renal phosphate wasting, hypophosphatemia, elevated 1,25(OH)2D synthesis, mild hypercalcemia, hypercalciuria, and nephrolithiasis [11]. Osteopenia has also been documented in patients with SLC9A3R1 variants, and PTH and FGF23 levels have been reported to remain within the normal range [85].
4. Dent’s disease
Dent’s disease is classified into two subtypes, type 1 and type 2. Dent’s disease 1 (MIM 300009), also known as X-linked nephrolithiasis type 2, X-linked recessive nephrolithiasis with renal failure, or X-linked recessive nephrolithiasis type 1, is characterized by proximal tubular dysfunction, including low-molecular-weight proteinuria, hypercalciuria, glucosuria, aminoaciduria, uricosuria, hematuria, and nephrocalcinosis [86]. This disorder is caused by inactivating variants in CLCN5, which encodes the chloride voltage-gated channel 5. Dent’s disease 1 may progress to chronic kidney disease in 30%–80% of patients by the third to fifth decade of life [87]. The underlying genetic defects are heterogeneous, and no clear genotype–phenotype correlation has been demonstrated. Because of its X-linked inheritance, the disease rarely occurs in females and is generally milder when present [88].
Dent’s disease 2 (MIM 300555), also known as oculocerebrorenal syndrome (Lowe syndrome), results from variants in the OCRL1 gene, which encodes inositol polyphosphate 5-phosphatase [89]. The clinical manifestations of this X-linked recessive disorder are similar to those of Dent’s disease 1. Genetic analysis is therefore required to distinguish between the two disease types. Although CLCN5 variants are detected in approximately 50%–60% of cases with Dent’s disease and OCRL1 variants in 15%–20%, no causative variants are identified in the remaining cases [86,89].
5. Other causes of tubulopathy
In addition to the conditions described above, many genetic and acquired causes of proximal renal tubulopathy can lead to hypophosphatemia through increased renal phosphate loss. These disorders can cause urinary losses of phosphate, calcium, sodium, amino acids, glucose, and bicarbonate. They may therefore cause metabolic acidosis, hyponatremia, hypophosphatemia, hypokalemia, and hypochloremia. Hypophosphatemia leads to rickets of varying severity, osteomalacia, and short stature. Inborn metabolic disorders (cystinosis, tyrosinemia, hereditary fructose intolerance, lysinuric protein intolerance, glycogen storage disease type 1, galactosemia, mitochondrial cytopathies, metachromatic leukodystrophy, Wilson disease), acquired causes (amyloidosis, multiple myeloma, burns, nephrotic syndrome, anorexia nervosa, and renal transplantation), and drugs (cisplatin, tetracycline, salicylate, valproate, rifampicin, aminoglycoside, ifosfamide) are recognized causes of tubulopathy.
The evaluation algorithm for hypophosphatemia in children is shown in Fig. 3.
Algorithm for the evaluation of hypophosphatemia in children. PTH, parathyroid hormone; TmP/GFR, tubular maximum reabsorption of phosphate per glomerular filtration rate; HR, hypophosphatemic rickets; XLHR, X-linked HR; ADHR, autosomal dominant HR; FGF23, fibroblast growth factor 23; ARHR, autosomal recessive HR; TIO, tumor-induced osteomalacia; ENS, epidermal nevus syndrome; MAS, McCune-Albright syndrome; OGD, osteoglophonic dysplasia; OPSMD, opsismodysplasia; HHRH, hereditary HR with hypercalciuria; NPHLOP1 and 2, HR with nephrolithiasis and osteoporosis type 1 and 2; FRTS2, Fanconi renotubular syndrome 2; HCINF2, infantile hypercalcemia type 2; 1,25(OH)2D, 1,25-dihydroxyvitamin D.
6. Treatment of FGF23-dependent HR
Conventional therapy remains a widely used treatment option for FGF23-dependent HR worldwide. However, in recent years, targeted treatment strategies have introduced new therapeutic options for selected patients. Conventional therapy, comprising oral phosphate supplementation and active vitamin D (calcitriol), is similar for XLHR, ADHR, ARHR, and other rare forms of HR. In contrast, the targeted biologic agent burosumab, an anti-FGF23 monoclonal antibody, has been approved for the treatment of XLHR and TIO.
The main goal in the treatment of these diseases is to reduce the level of FGF23 and restore bone mineralization. Conventional treatment consists of lifelong oral phosphate and active vitamin D (calcitriol). Calcitriol is recommended at 25–70 ng/kg/day in 2 divided doses, and elemental phosphate at 30–70 mg/kg/day in 4–6 divided doses [2]. The primary objective of conventional therapy is to maintain serum ALP levels within the high-normal range. Normalization of serum phosphate should not be targeted because aggressive phosphate therapy can cause diarrhea, secondary hyperparathyroidism, increased FGF23 production, nephrocalcinosis, and renal failure [32,90]. In addition, serum phosphate alone is not a reliable marker of treatment response because of its rapid fluctuations. Therefore, reductions in ALP, radiographic improvement in rickets, and increased growth velocity are more meaningful indicators of therapeutic response [2]. Conventional calcitriol and phosphate therapy can improve bone mineralization, promote healing of rickets, and increase growth velocity; however, skeletal deformities may not be completely prevented in some patients [2,90].
Phosphate salts (sodium phosphate and potassium phosphate) are generally used for phosphate replacement and are available as tablets or solutions. Phosphate-Sandoz® tablets provide a high dose of phosphate in the form of monobasic sodium phosphate. Each tablet contains 500 mg elemental phosphate (16.1 mmol phosphate), 469 mg sodium (20.4 mmol Na+), 123 mg potassium (3.1 mmol K+), and 800 mg citric acid. If tablets are unavailable, Joulie’s solution can be used in children. The solution is prepared by dissolving 136 g of dibasic sodium phosphate and 58.8 g of phosphoric acid in distilled water to a final volume of 1,000 mL. The final solution contains 30.4 mg of elemental phosphate per mL. More frequent division of the phosphate dose may reduce serum phosphate fluctuations and the frequency of diarrhea, the most common adverse effect of this therapy.
Clinical and anthropometric assessments (including height, weight, head circumference, intercondylar distance, and intermalleolar distance), as well as laboratory evaluations (serum Ca, P, ALP, PTH, creatinine, and urine Ca/Cr) should be performed every 3 months. After tooth eruption, dental examinations should be performed twice yearly. Renal ultrasonography is recommended before treatment and should be repeated at 1- to 2-year intervals during follow-up to monitor for nephrocalcinosis [2]. Skeletal radiographs are recommended before treatment and annually thereafter to assess rickets. In patients with an abnormal cranial shape, headache, or neurologic symptoms, fundoscopy and brain MRI should be performed [4].
Calcitriol therapy should be titrated according to serum PTH levels and urinary calcium excretion. The goal is to administer the optimal dose that suppresses PTH, maintains normocalcemia, and does not induce hypercalciuria. The urine calcium/creatinine ratio varies by age: <0.8 in the first 6 months, <0.6 at 7–24 months, <0.53 at 1–3 years, <0.39 at 3–5 years, <0.28 at 5–7 years, and <0.21 after 7 years of age. Hypercalciuria may also be defined as urinary calcium excretion >4 mg/kg/day in a 24-hour urine collection. In the presence of hypercalciuria, the calcitriol dose should be reduced. To suppress nocturnal PTH secretion, it is recommended that the evening dose of calcitriol be higher than the morning dose [2].
High-dose phosphate therapy is closely associated with nephrocalcinosis [2,32]. The prevalence of nephrocalcinosis in patients with HR receiving combined calcitriol and phosphate therapy has been reported to range from 33% to 80%. This complication most commonly develops during the first 3–4 years of treatment [2,32,91,92]. Long-term high-dose phosphate therapy has also been associated with secondary and even tertiary hyperparathyroidism [93,94]. Cinacalcet has been reported to be an effective treatment option for tertiary hyperparathyroidism in children with HR [95]. Therefore, phosphate should be used at the lowest appropriate dose in patients with HR, and patients should be monitored for hyperparathyroidism and nephrocalcinosis.
Although rickets may improve with conventional therapy, complete remission is not always achieved [2]. Mild to moderate manifestations may persist. For persistent deformities, pediatric orthopedic specialists may recommend corrective bracing; however, these devices are often poorly tolerated by children. Surgical correction should be considered when appropriate. Femoral and tibial hemiepiphysiodesis is recommended as an alternative surgical approach for lower-extremity deformities in patients with XLHR younger than 10 years [96]. In older children and adolescents, osteotomy is generally preferred [2].
Short stature is a common feature of XLHR, with relative preservation of trunk length. Calcitriol and phosphate therapy can improve rickets and increase growth velocity. However, some patients with XLHR do not achieve adequate growth despite appropriate treatment [2,32,97]. This may be related to delayed treatment initiation or impaired growth hormone (GH) secretion [97]. Although recombinant human GH (rhGH) has been evaluated in several studies and can transiently increase growth velocity [98,99], it has not been shown to improve skeletal disproportion or final height [18,100]. Consequently, routine rhGH use in children with XLHR is not recommended.
Recognition of the central role of FGF23 in the pathogenesis of these disorders prompted investigation of more specific therapies aimed at reducing its biological activity. In a study of 28 adults with XLHR, four months of treatment with KRN23, a recombinant IgG1 monoclonal antibody that binds to and inhibits FGF23 (anti-FGF23 antibody; burosumab), significantly increased serum phosphate and 1,25(OH)2D levels and improved renal phosphate reabsorption [101]. The half-life of burosumab has been reported to be 13–19 days after subcutaneous administration and 8–12 days after intravenous administration. Serum phosphate concentrations remained above baseline for up to 4 weeks after treatment [97,99].
Burosumab was approved for the treatment of XLHR by the European Medicines Agency in February 2018 and by the U.S. Food and Drug Administration (FDA) in April 2018 for children aged ≥1 year with radiographic evidence of bone disease and for growing adolescents. The approved age was subsequently lowered to ≥6 months. Numerous studies have demonstrated that burosumab improves TmP/GFR, serum ALP and phosphorus levels, skeletal manifestations, and linear growth and is well tolerated in children [102-105]. Burosumab is particularly recommended for patients with XLHR who have persistent radiographically significant rickets despite conventional treatment, poor treatment adherence, or treatment-related complications [106].
Conventional therapy should be discontinued at least 1 week before burosumab is initiated. In children, burosumab is recommended to be initiated at 0.4 mg/kg (0.8 mg/kg according to FDA approval), administered subcutaneously every 2 weeks [107]. The dose should be titrated in 0.4-mg/kg increments to achieve serum phosphorus concentrations within the low- to mid-normal (peak) range for age, or just below the normal or low-normal range, up to a maximum of 2.0 mg/kg (maximum total dose, 90 mg) [18,107-111]. In pediatric studies, the mean maintenance dose was approximately 1.0 mg/kg [106,109]. Burosumab dose adjustments should not be made more frequently than every 4 weeks. Peak serum concentrations occur 7–11 days after burosumab administration. During dose titration, fasting serum phosphate levels should be monitored between injections—ideally 12–14 days after the last dose—to detect possible hyperphosphatemia [106]. Steady state is achieved after approximately three months of stable dosing, and fasting serum phosphate should preferably be measured immediately before the next injection to assess dose adequacy. Burosumab should be withheld if fasting serum phosphate rises above the normal range. Treatment may be restarted at approximately half the previous dose once serum phosphate falls below the normal range [106,109].
Long-term clinical trials have demonstrated that burosumab significantly increases serum phosphate levels, elevates active vitamin D concentrations, and enhances renal phosphate reabsorption, resulting in radiographic healing of rickets [110]. Furthermore, its therapeutic effects extend beyond biochemical improvements: burosumab may help prevent lower-limb deformities, significantly reduce rickets severity scores, improve height outcomes, and reduce the overall symptom burden associated with chronic hypophosphatemia [111]. Studies have shown that the beneficial effects of burosumab do not differ by age or sex. However, compared with younger children, adolescents generally require a lower weight-based maintenance dose [110]. In pediatric studies, an every-2-week burosumab regimen resulted in more rapid normalization of ALP, improved renal phosphate reabsorption, and more consistent serum phosphorus levels throughout the dosing interval than an every-4-week regimen [105]. Quality-of-life assessments have demonstrated improved physical functioning, reduced pain, greater physical activity, and better overall well-being [18,110,111]. Burosumab also has a favorable safety profile, with a low incidence of adverse events, including injection-site reactions, hypersensitivity, and gastrointestinal symptoms. However, an increased risk of dental abscesses has been reported compared with conventional therapy. Given its well-documented efficacy and safety, burosumab should be considered for early initiation in children aged ≥6 months with XLHR rather than conventional therapy [18].
Burosumab is also effective for TIO in children and adolescents. Its use for TIO has been approved by the FDA and Japanese health authorities [106,112,113]. Children with TIO aged 2–18 years may be treated with burosumab at 0.4 mg/kg every two weeks, up to a maximum of 2.0 mg/kg [106,113].
7. Treatment of FGF23-independent HR
Unlike FGF23-dependent forms of HR (XLHR, ADHR, etc.), calcitriol is not used in this group and is contraindicated because it may increase urinary calcium excretion. In FGF23-independent hypophosphatemia, the response to phosphate therapy alone, administered in 4–6 divided doses, is generally excellent [2,4]. Following phosphate supplementation, serum 1,25(OH)2D concentrations decrease and urinary calcium excretion returns to normal. Muscle pain, bone pain, and skeletal manifestations of rickets also improve. A sodium-restricted diet may also be beneficial because it can help reduce urinary calcium excretion [2].
Notes
Conflicts of interest
No potential conflict of interest relevant to this article was reported.
Funding
This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author contribution
Conceptualization: OK, SA; Data curation: OK; Formal analysis: SA; Methodology: SA; Visualization: SA; Writing - original draft: OK, SA; Writing - review & editing: OK, SA
